Get the Daily Brief
Latest Biotech News
Plasma LPS levels forecast mortality among acutely ill children
A multicenter study in low‑ and middle‑income countries identified plasma lipopolysaccharide (LPS) concentration as a strong predictor of mortality in acutely ill children. Researchers measured...
mRNA retools allogeneic stem cells: DC‑25 emerges
Researchers report an mRNA-based engineering approach that upgrades mesenchymal stem cells (MSCs) to create an off-the-shelf allogeneic immunotherapy called DC-25. The study, led by the team...
HCW11‑018 T‑cell engager shows pancreatic activity
HCW Biologics reported preclinical antitumor activity for HCW11‑018, a T‑cell engager designed for pancreatic cancer (e18000a5cb072078). The company presented in vitro and in vivo data showing...
TEAD inhibitor VT‑3989 targets NF2‑deficient tumors
Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed aggressive NF2‑deficient tumor growth in vitro and in vivo (68e05edcb0400dd1). The company showed...
GD2 ADC M‑3554 posts potent antitumor effects
A new antibody‑drug conjugate, M‑3554, targeting GD2 showed robust antitumor activity in neuroblastoma and soft tissue sarcoma models (168c1410c7e7c25f). The ADC uses a β‑glucuronide cleavable...
Boehringer discloses cGAS inhibitors for inflammatory and fibrotic disease
Boehringer Ingelheim reported discovery of cyclic GMP‑AMP synthase (cGAS) inhibitors with potential across autoinflammatory and fibrotic indications (f0d08b4fdbedcc05). The company’s disclosure...
Lilly reports RXFP1 agonists for cardiorenal and kidney disease
Eli Lilly disclosed a series of RXFP1 (relaxin receptor 1) agonists described as candidates for pulmonary hypertension, kidney disease, and cardiorenal conditions (cdd0d021f719f7ee). The compounds...
Kymera patents STAT6 inhibitors for broad disease portfolio
Kymera Therapeutics revealed new patents on STAT6 inhibitors aimed at oncology, inflammation, fibrosis, and metabolic indications (d3aace0d1d6f498c). The disclosures describe small molecules...
Single 2‑ml mirikizumab injection proves bioequivalent to two 1‑ml doses
A clinical pharmacology study demonstrated that a single 2‑ml subcutaneous injection of mirikizumab is bioequivalent to two 1‑ml injections when dosed in healthy volunteers (d3fe7f949991ed57). The...
Sibiriline: a dual inhibitor of necroptosis and ferroptosis
Scientists announced Sibiriline, a small molecule that concurrently blocks necroptosis and ferroptosis—two regulated cell‑death pathways implicated in degenerative and inflammatory disorders...
Complement gene variants shape pancreatic cancer susceptibility and outcomes
A Nature Communications study mapped how genetic variation in complement system genes impacts pancreatic cancer risk and prognosis (5824da7fa241d818). The analysis integrated genomic datasets to...
Eli Lilly unveils RXFP1 agonists — broad therapeutic targets
Eli Lilly disclosed a new series of RXFP1 (relaxin receptor 1) agonists in a recent patent disclosure, positioning the compounds across indications that include pulmonary hypertension, chronic...
Boehringer Ingelheim files cGAS inhibitors — autoimmune and fibrotic stakes
Boehringer Ingelheim disclosed novel cyclic GMP‑AMP synthase (cGAS) inhibitors designed to blunt innate immune sensing in disorders driven by aberrant interferon signalling. The company’s filing...
Kymera patents STAT6 inhibitors — inflammation to oncology opportunity
Kymera Therapeutics disclosed novel STAT6 inhibitors in a recent patent publication, broadening its targeted‑protein degradation and small‑molecule portfolio into the STAT transcription factor...
Telix faces shareholder class action notice — litigation risk for radiopharma
A U.S. law firm issued a notice seeking Telix Pharmaceuticals shareholders potentially harmed during a defined class period, prompting investor scrutiny of Telix’s commercial and disclosure...
Kedrion wins EU orphan tag for aceruloplasminemia — rare‑disease push
Kedrion SpA secured European orphan drug designation for its investigational plasma‑derived therapy for congenital aceruloplasminemia, the company announced. The EMA’s orphan tag applies to a...
Vivace TEAD inhibitor shows preclinical hits in NF2 models — meningioma angle
Vivace Therapeutics reported preclinical efficacy for VT‑3989, a TEAD inhibitor showing activity in NF2‑deficient meningioma models and other aggressive tumor types. Company data presented include...
M‑3554 ADC shows anti‑tumor activity — GD2 target in sarcoma and neuroblastoma
An antibody‑drug conjugate, M‑3554, demonstrated strong antitumor activity in neuroblastoma xenograft models and shows engineered features intended to reduce GD2‑associated pain, according to...
mRNA engineering bolsters allogeneic MSC therapy — DC‑25 emerges
Researchers reported mRNA engineering of mesenchymal stem cells (MSCs) to create DC‑25, an allogeneic cell therapy designed to enhance immunomodulatory function and overcome limitations of...
MAP‑X maps malaria protein networks — dynamic interactome across lifecycle
Scientists introduced MAP‑X, a technique that charts protein complex dynamics across Plasmodium falciparum’s intraerythrocytic developmental cycle, revealing stage‑specific interactions that drive...